

PATIENT INFORMATION

<u>[1] Patient Name</u>	<u>[2] Date of Birth</u>	<u>[3] Height</u>	<u>[4] Weight</u>
<u>[5] Patient Address</u>	<u>[6] Patient Telephone #</u>	<u>[7] Patient Mobile #</u>	
<u>[8] Referring Provider</u>	<u>[10] Provider Telephone #</u>	<u>[11] Provider Fax#</u>	

[12] SIGNS AND SYMPTOMS (REQUIRED)

Type of cancer Histologically Proven Suspected
Please check Radiopharmaceutical
 FDG

CPT Codes
 If provided a specific CPT code, please provide.

INSURANCE INFORMATION

[13] Primary Insurance [14] Subscribers Insurance ID #

Secondary Insurance Insurance Prior Authorization #

CMS/APPROPRIATE USE CRITERIA (FOR MEDICARE PART B PATIENTS ONLY)

NPI# Name of CDSM Consulted (software used) **Determination Result (check one):**
 1) Adheres to 2) Does Not Adhere to 3) Not Applicable

[15] (Check ONE and fill out corresponding section completely)

Initial Treatment Strategy

Diagnosis: Abnormal finding of _____
 Based on _____
Check one

To determine whether the patient is a candidate for an invasive diagnosis or therapeutic procedure;

To determine the optimal anatomic location for an invasive procedure; or

To determine the anatomic extent of the tumor when the treatment recommendations depend on the extent,

Initial Staging: of confirmed newly diagnosed cancer
Check one

To determine whether the patient is a candidate for an invasive diagnosis or therapeutic procedure;

To determine the optimal anatomic location for an invasive procedure; or

To determine the anatomic extent of the tumor when the treatment recommendations depend on the extent.

Other (e.g., Alzheimer's Disease). Please list reason for scan here:

Subsequent Treatment Strategy

Restaging: (after the completion of treatment)
Check one

Status post the completion of treatment for the purpose of detecting residual disease
 Last date of treatment: _____
 Type of treatment: _____

Detecting suspected recurrence, or metastasis of previously treated cancer:
 Site of suspected recurrence / metastasis: _____
 Based on: _____

Determine the extent of a known recurrence.
 Confirmed by: _____

PET/CT is being used to potentially replace one or more imaging studies that (1) is being utilized to determine extent of known recurrence of (2) provided insufficient information for the clinical management of the patient.

Monitoring Tumor Response: During Treatment
Check one

Chemotherapy Radiotherapy Other (specify): _____

[16] PRESCREENING QUESTIONNAIRE

Prior Studies/Treatment

Pregnant: <input type="checkbox"/> Y <input type="checkbox"/> N	Previous: <input type="checkbox"/> CT <input type="checkbox"/> MRI <input type="checkbox"/> PET/CT	Where: _____	When: _____
Diabetes: <input type="checkbox"/> Y <input type="checkbox"/> N	Pathology: <input type="checkbox"/> Y <input type="checkbox"/> N	Where: _____	When: _____
	Radiation Therapy: <input type="checkbox"/> Y <input type="checkbox"/> N	Provider: _____	When: _____
	Chemotherapy: <input type="checkbox"/> Y <input type="checkbox"/> N	Provider: _____	When: _____

[17] **Authorized Treating Provider's Signature:** (Stamps Not Accepted)

[18] **NPI #**

[19] **Date**

Services provided by

Please FAX this form (and recent office notes, radiology reports and pathology reports) to Scheduling Department after patient's examination has been scheduled.